Tag: AI Drug Discovery
Boehringer Ingelheim taps Immunai AI platform in $15 million deal
Boehringer Ingelheim pays $15M for Immunai's AI platform to find shared T-cell targets across cancer and autoimmune disease.
Mount Sinai AI model maps how genes function together in cells
Scientists at Mount Sinai developed a gene set foundation model that learns how genes behave across thousands of biological contexts,…
Over 173 AI-designed drugs now in trials as FDA decision nears
More than 173 AI-originated drug programs are in clinical development as of early 2026, with the first potential FDA approval…
Chai Discovery raises $400 million Series C for AI drug design
The startup behind AI molecule models used by Lilly, Novartis and Pfizer hits a $3.8 billion valuation.
Insilico and SK Biopharm ink $2.5 billion AI drug discovery deal
The partnership targets neuroimmune and CNS disorders using Insilico's Pharma.AI engine, with $18 million in upfront payments and milestone-based upside.
OpenAI launches GPT-Rosalind for life sciences research
The frontier reasoning model is designed to accelerate drug discovery and biological research across chemistry, protein engineering, and genomics.
Chai Discovery raises $400M at $3.8B valuation for AI drug design
The AI biotech startup triples its valuation in eight months with backing from Lilly, Pfizer and Novartis partnerships.
How Machine Learning Is Reshaping Pharmaceutical R&D
AI is reshaping pharmaceutical R&D from target identification through clinical trial optimization, compressing drug discovery timelines and unlocking therapeutic targets…